ABSTRACT
We used primary and linked secondary healthcare data to investigate the incidence of clinically diagnosed influenza/influenza-like-illness (ILI) by ethnicity in England from 2008-2018. We identified higher incidence rate ratios for influenza/ILI among South Asian (1.70, 95% CI 1.66-1.75), Black (1.48, 1.44-1.53) and Mixed (1.22, 1.15-1.30) groups compared to White ethnicity.
People from ethnic minority backgrounds are represented disproportionately among patients with severe COVID-19. Recent research has found people of Black and South Asian ethnicity have increased risk of SARS-CoV-2 infection, COVID-19-related hospitalization and death, independent of deprivation, occupation, household size, and underlying health conditions(1,2).
The COVID-19 pandemic has reinforced the importance of seasonal influenza vaccination. By preventing influenza-related hospitalization, vaccination can minimize the risk of hospital-acquired COVID-19 (co-) infection for these individuals and reduce health service pressures, particularly the need for isolation of patients with respiratory symptoms awaiting COVID-19 test results.
In the UK, influenza vaccine is routinely recommended for adults aged ≥65 years, or people <65 years with underlying health conditions. These recommendations formed the basis of the original guidance to identify patients at moderate- and high-risk of COVID-19. Influenza vaccine recommendations were expanded for the 2020/21 season to include all adults ≥50 years(3). However, vaccine uptake among clinical risk groups is low, particularly for Black and Mixed Black ethnic groups(4). In addition, people of non-White ethnicity have higher risk of severe outcomes following influenza infection(5,6). It is unclear whether this is driven by the risk of infection or complications, with most research focused on distal outcomes rather than initial infection risk.
Here we investigate the incidence of influenza and influenza-like-illness (ILI) by ethnicity from 2008-2018 among people not eligible for routine influenza vaccination, to consider disparities in infection risk.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form (www.icmje.org/coi_disclosure.pdf). A.B. has received grants from Astra Zeneca, UK Research and Innovation (UKRI), and the NIHR. R.M. has received grants from the Wellcome Trust and personal fees from Amgen. M.R. reports that Public Health England Immunisation and Countermeasures Division has provided vaccine manufacturers with post-marketing surveillance reports on vaccine-preventable infection which the companies are required to submit to the UK Licensing Authority in compliance with their Risk Management Strategy, and a cost recovery charge is made for these reports. L.S. has received grants from the NIHR, the Wellcome Trust, Glaxo-Smith Kline, the British Heart Foundation, Diabetes UK, the Newton Fund, and UKRI; he is also a non-executive direction of the Medicines and Healthcare products Regulatory Agency (MHRA). C.W.-G. has received speaker fees from Sanofi Pasteur.
Funding Statement
This work was supported in part by by the British Heart Foundation [FS/18/71/33938] who fund a Non-Clinical PhD Studentship for J.A.D., the Wellcome Trust [201440/Z/16/Z] who fund an Intermediate Clinical Fellowship for C.W.-G, and the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Immunisation at the London School of Hygiene and Tropical Medicine in partnership with Public Health England, who fund J.W., H.M., L.S. and M.R. The funders had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, or Public Health England.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the London School of Hygiene and Tropical Medicine Research Ethics Committee (Reference: 17894) and by the CPRD Independent Scientific Advisory Committee (Protocol number: 19_209A2).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos